How are GMO regulations impacting clinical development in Europe?

Listen now

Description

In this episode of Conversations in Drug Development, our host Dr Harriet Edwards, is joined by Director of Regulatory Affairs, Dr Sabine Ruehle, to discuss the challenges of navigating genetically modified organism (GMO) regulations in clinical trials within Europe. This discussion helps decipher the nuanced environment of GMOs and their associated risks unique within the European framework. Join us as we explore the outdated definition of GMOs, the complexities of their classification, and the impact of genome editing technologies.

More Episodes

See all »

Conversations in Drug Development

Published 04/25/24

US drug development: The latest regulatory trends and initiatives

In this episode of Conversations in Drug Development, host Harriet Edwards is joined by Katie Rudnick and Dr Julie Warner from Boyds to discuss US regulatory trends and initiatives at the FDA.

Published 03/19/24

The regulatory challenges of rare disease drug development

To celebrate Rare Disease Day, we are back with another Conversation in Drug Development, this time discussing the unique challenges of rare disease drug development. Dr Eric Hardter, Associate Director of Regulatory Affairs at Boyds, joins our host Harriet Edwards to explore the need for early...

Published 02/28/24